Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Taltz® (ixekizumab) Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis

[PR Newswire] – INDIANAPOLIS, May 2, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that Taltz ® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now … Read more on this. Eli Lilly and Company (LLY) , valued at $81.43B, started the session at $75.95. Today’s price range has been between $75.87 and $77.08 per share with a one year range of $67.88 to $92.85. LLY shares are currently priced at 21.22x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -6.99x forward p/e ratio. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.70%. Consensus earnings for the current quarter by the 18 sell-side analysts covering the stock is an estimate of $0.86 per share, which would be $0.04 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $3.56 which would be a $0.13 improvement than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $5.14 Billion. If realized, that would be a 3.21% increase over the year-ago quarter. In terms of ratings, Societe Generale Initiated LLY at Hold (Apr 6, 2016). Previously, BMO Capital Markets upgraded LLY from Market Perform to Outperform. When considering if perhaps the stock is under or overvalued, the average price target is $95.86, which is 26.21% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis Stock Update (NYSE:LLY): Ixekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept Company Update (NYSE:LLY): Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.